#USA #New York #Aignostics #Tumor Microenvironment #Atlas HE-TME

Aignostics Launches Atlas HE-TME

Aignostics, a pioneering AI firm, has recently announced the general availability of its revolutionary application, Atlas HE-TME. This innovative tool promises to transform the analysis of tumor microenvironments (TME) by offering comprehensive insights from routine Hematoxylin and Eosin (HE) stained slides. The application had already demonstrated its effectiveness during early access pilots with prominent biopharmaceutical partners, making it a highly anticipated launch within the medical research community.

Addressing Critical Bottlenecks in Cancer Research

The Atlas HE-TME application addresses a significant challenge in cancer research: the need for timely and accurate analysis of TME data. Traditional methods can be cumbersome, costly, and overly complex, often involving specialized staining techniques or multiplexing. Atlas HE-TME simplifies this process by providing quick and thorough analyses of whole-slide images without the need for such specialized procedures. In just a matter of hours, researchers can extract valuable information regarding immune cell populations, their spatial relationships, and overall tissue architecture across various cancer types.

The groundwork for Atlas HE-TME was laid through a collaboration between Aignostics, the Mayo Clinic, and Charité Berlin, utilizing the advanced Atlas foundation model. This collaboration has fostered an application that not only ensures high accuracy but also allows for extensive quality control. Atlas HE-TME offers profound insights, delivering analyses of seven distinct tissue types, nine cell classifications, and an impressive array of over 5,000 higher-order quantitative metrics for each image processed.

User-Friendly and Versatile

One of the standout features of Atlas HE-TME is its accessibility. Designed as a self-service application, it allows users to navigate its capabilities with ease. Moreover, Aignostics has plans to implement integrations with major image management systems soon, which will further enhance its functionality and reach.

Aignostics has put in robust validation measures across various labs and scanners to ensure that the platform's performance mirrors real-world conditions. New partners can request detailed validation metrics to ascertain the application's reliability.

An Industry Game Changer

Dr. Frederick Klauschen, Co-Founder of Aignostics, praised the application, stating, "This is the first time I have seen a model that demonstrates consistently high accuracy across multiple cancer indications with exceptional robustness." Viktor Matyas, CEO of Aignostics, emphasized the significance of understanding the TME, remarking that existing approaches are often limited. With the introduction of Atlas HE-TME, researchers can now access high-quality results without the barriers of traditional methodologies.

Another major advantage of the Atlas HE-TME is its versatility. It supports various research applications, from the swift identification of tumors exhibiting immune infiltration to the integration of HE data with spatial transcriptomics for in-depth cell niche analyses. Initially, the application will focus on breast, bladder, colorectal, liver, and lung cancers for biopharma partners, with plans to extend offerings to academic institutions and additional cancer types in the near future.

Opportunities for Researchers

Organizations interested in exploring the capabilities of Atlas HE-TME can visit Aignostics' official website for more information regarding a free trial. This expansion into the research domain promises to bridge the gap between traditional methods and modern technology, paving the way toward breakthroughs in cancer treatment and understanding.

About Aignostics

Founded in 2020 as a spin-off from Charité Berlin, Aignostics leverages its cutting-edge artificial intelligence technologies to turn intricate pathology data into vital insights for precision medicine. With a dedicated team of over 120 professionals and operations in both Berlin and New York, Aignostics is committed to delivering top-tier products that support every milestone in drug development, from initial discovery through clinical trials to companion diagnostics.

For more information, visit Aignostics' website and follow them on LinkedIn.